Retatrutide: what a telehealth brand needs to know before selling it
The short answer
No. Retatrutide is not FDA approved, is not on any shortage list, and does not qualify for compounding under 503A or 503B, so no US pharmacy can lawfully make it for a patient. The FDA has already sent warning letters to telehealth companies marketing it. The only lawful routes to it are a registered clinical trial or the manufacturer's expanded access programme, and neither is something a brand sells. If a supplier offers it to you, that is information about the supplier.
Why can it not be compounded?
Compounding a copy of a commercial drug needs a legal basis, and retatrutide has none available to it.
It is not approved, so there is no approved product to compound a version of. It is not on the shortage list, so the shortage exception that briefly covered semaglutide and tirzepatide does not reach it. And its active ingredient is not on the 503A bulks list, which is the other route a pharmacy could use. Three doors, all shut.
A research-use label on a vial does not change this, and neither does a telehealth visit in front of it. Those are the two framings sellers reach for, and the FDA has addressed both.
What are the lawful routes, and can a brand use them?
Two, and neither is a product.
A registered clinical trial. Patients enrol, the sponsor supplies the drug, and nobody sells anything. You can tell a patient this route exists. You cannot be in the middle of it.
Expanded access. The manufacturer confirmed in August 2026 that patients can apply, submitted by a clinician for a narrow group. Again, it runs between the clinician, the patient and the sponsor.
There is a version of being useful here that does not involve selling. A brand whose patients keep asking about retatrutide can say plainly what it is, where it stands, and why the offers they are seeing online are not legitimate. That answer is worth more than most content about products you do sell, and almost nobody is giving it.
What happens to a brand that sells it anyway?
The visible consequence is a warning letter, published on the FDA's own site with your company name on it, which is a permanent search result for anyone who looks you up.
The expensive consequences come after. A payment processor reading that letter re-underwrites you. An advertising platform reading it pulls your certification. A pharmacy partner reading it stops taking your prescriptions, and a provider network reading it stops reviewing your intakes. None of those decisions involve the FDA, and all of them land faster.
The thing to understand about the sellers currently offering it is that most of them are not pharmacies. The chain tends to end at a supplier shipping vials labelled for research, which is a different business with different exposure, and the brand in front of it is the one with a public name and a merchant account.
What should you do when a supplier offers it?
Treat it as a test of the supplier rather than an opportunity. A pharmacy that offers to compound retatrutide today is telling you what it is willing to do with the rules, and that willingness will not be limited to one molecule.
The same questions sort it quickly. Which registered manufacturer supplies the ingredient, and are they FDA registered and compliant with good manufacturing practice? What legal basis are you compounding this under? Can I see the certificate of analysis for the current lot? A legitimate pharmacy has those answers to hand.
If retatrutide is eventually approved, it will be sold the way every approved drug is sold, by prescription through the normal channel. A brand already running intake, provider review and pharmacy routing adds it that week. There is no advantage being bought by selling it early, only exposure.
Questions
Is retatrutide FDA approved?
No. It is in clinical trials. There is no approved labelling, no approved indication and no approved product.
Can a compounding pharmacy make retatrutide legally?
No. It is not approved, not in shortage, and not on the 503A bulks list, so none of the three routes to lawful compounding is open.
What about vials labelled for research use only?
That label is the point, not a loophole. Research chemicals are not prescription medicines and selling them for human use is a different and worse exposure than compounding.
Has the FDA actually acted on this?
Yes. It has warned telehealth companies for marketing retatrutide, including directly to consumers.
When could a brand sell it?
If and when it is approved, through the ordinary prescription channel. A store already running intake, provider review and pharmacy routing can add it as soon as that happens.